Alar PharmaceuticalsROCO:6785 52 Altman Z-Score is 56.66 as of Jul. 13, 2026, which is 61% below its 10-year median of 145.53. GuruFocus rates ROCO:6785 with a GF Score™ of 52/100 and a GF Value™ of NT$90.64 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 953 Drug Manufacturers companies, Alar Pharmaceuticals ranks better than 99.37% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 56.66 is strong.
Alar Pharmaceuticals has a Altman Z-Score of 56.66, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Alar Pharmaceuticals's Altman Z-Score or its related term are showing as below:
ROCO:6785'
s Altman Z-Score Range Over the Past 10 Years
Min: 56.66 Med: 145.53 Max: 484.04
Current: 56.66
During the past 9 years, Alar Pharmaceuticals's highest Altman Z-Score was 484.04. The lowest was 56.66. And the median was 145.53.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Alar Pharmaceuticals Altman Z-Score Related Terms
Alar Pharmaceuticals Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Alar Pharmaceuticals's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alar Pharmaceuticals's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alar Pharmaceuticals Altman Z-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alar Pharmaceuticals's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Alar Pharmaceuticals's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Alar Pharmaceuticals's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.9158
+
1.4
*
0.0459
+
3.3
*
-0.0317
+
0.6
*
92.6711
+
1.0
*
0.0011
=
56.66
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Alar Pharmaceuticals (ROCO:6785) has a Altman Z-Score of 56.66 as of Jul. 13, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Alar Pharmaceuticals and its competitors. This is 61% below median its historical median of 145.53. Over the past decade, Alar Pharmaceuticals' Altman Z-Score has ranged from 56.66 to 484.04. According to the industry distribution chart, Alar Pharmaceuticals ranks #6 out of 953 companies in the Drug Manufacturers industry, placing it in the top 0.59999999999999%.
Is Alar Pharmaceuticals' Altman Z-Score too high?
Alar Pharmaceuticals' current Altman Z-Score of 56.66 is 61% below median its 10-year median of 145.53. Over the past 10 years, this metric has ranged from a low of 56.66 to a high of 484.04. The Drug Manufacturers industry median Altman Z-Score is 3.25. Alar Pharmaceuticals' value of 56.66 is 1643.4% above this industry median. Based on the distribution chart, Alar Pharmaceuticals ranks #6 out of 953 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Alar Pharmaceuticals has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alar Pharmaceuticals' Altman Z-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Alar Pharmaceuticals ranks #6 out of 953 companies for Altman Z-Score. This places Alar Pharmaceuticals in the top 1% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 3.25. Alar Pharmaceuticals' value of 56.66 is 1643.4% above this benchmark. Historically, Alar Pharmaceuticals' own Altman Z-Score has ranged from 56.66 to 484.04 over the past decade. While the company's 10-year median is 145.53 vs. the industry median of 3.25, Alar Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Drug Manufacturers company?
The median Altman Z-Score among Drug Manufacturers companies is 3.25, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alar Pharmaceuticals's current Altman Z-Score of 56.66 is 1643.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Alar Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Altman Z-Score is 3.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alar Pharmaceuticals's current Altman Z-Score is 56.66, which is 61% below median its own 10-year median of 145.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alar Pharmaceuticals (ROCO:6785) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$90.64, compared to a current price of NT$117.00 — trading 29.1% above its estimated fair value. The current Altman Z-Score is 56.66, which is 61% below median its 10-year median of 145.53 and 1643.4% above the Drug Manufacturers industry median of 3.25. Alar Pharmaceuticals' overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Alar Pharmaceuticals (ROCO:6785), the current Altman Z-Score is 56.66 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alar Pharmaceuticals (ROCO:6785) Overvalued in 2026?
Based on GuruFocus' analysis, Alar Pharmaceuticals stock appears to be overvalued.
The current stock price of NT$117.00 is trading 29.1% above its estimated GF Value™ of NT$90.64.
GuruFocus considers Alar Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for ROCO:6785:
Altman Z-Score: 56.66 (61% below median its 10-year median of 145.53)
GF Value™: NT$90.64 vs. price of NT$117.00 (29.1% above fair value)
Industry Position: 1643.4% above the Drug Manufacturers median (#6 of 953)
No single metric tells the full story. See the ROCO:6785 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alar Pharmaceuticals Inc is a drug development company mainly engaged in the research and development of new drugs, sales of western pharmaceuticals, and medical devices. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and depressive disorder. The company currently has only a new drug development division, and its product pipeline comprises various drug candidates such as ALA-1000 (Buprenorphine), ALA-1300, ALA-2000 (Naltrexone), ALA-3000 (Ketamine), ALA-4000 (Apomorphine), and ALA-5000 (Third-generation antipsychotic). Geographically, the company generates maximum revenue from the USA and also has its presence in Taiwan and the United Kingdom.
52GF Score
Get the complete analysis for ROCO:6785
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6785 has been successfully added to your 
